Scarica l'app Stockscreener
63.65
0.03%
-0.02
Pre-mercato:
63.76
0.11
+0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$63.67
Aprire:
$63.8
Volume 24 ore:
8.16M
Relative Volume:
1.16
Capitalizzazione di mercato:
$25.41B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-7.8135
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+18.18%
1M Prestazione:
-5.01%
6M Prestazione:
+50.72%
1 anno Prestazione:
+136.71%
Intervallo 1D:
$62.33
$65.33
Intervallo di 1 settimana:
$54.62
$65.33
Portata 52W:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
63.65 | 25.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
The FDA approved the first mRNA flu vaccine for use in older adults. Here’s what to know - CNN
Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings? - TradingView
Moderna Begins First Human Trial of a Vaccine for the Ebola Strain Driving Congo's Outbreak - medicaldaily.com
Virus Strategy Yields Technology to Triple mRNA Lifespan — Published in Cell - finance.biggo.com
Moderna Vaccine Appeal Poised to Set Patent Liability Benchmark - Bloomberg Law News
Capital World Investors reports 5.6% Moderna (MRNA) stake in Schedule 13G filing - Stock Titan
Bank of America Corp DE Sells 388,494 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
The FDA Approved a New mRNA Flu Vaccine. Here’s What to Know - WTTW
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market - Yahoo Finance
Moderna Inc (MRNA): A Closer Look Behind a 59 GF Score - GuruFocus
RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers - Yahoo Finance
FDA Approves New Flu Shot Using COVID-Era Tech—Here’s Who Can Get It - Newsweek
1st mRNA flu vaccine gets FDA nod after rare U-turn. What the technology does & why it faced scrutiny - ThePrint
Moderna, Inc. (MRNA) Stock Analysis: Navigating Potential Amidst A -14.07% Downside - DirectorsTalk Interviews
Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc. - MarketBeat
Watch RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers - Bloomberg.com
Moderna | History, Innovation, Challenges, & Facts - britannica.com
Moderna, Inc. $MRNA Shares Acquired by Empowered Funds LLC - MarketBeat
Moderna jumps as FDA flu-shot approval reinforces recent business momentum - quiverquant.com
FAQ: What mFLUSIVA's Approval May Signal for the Future of mRNA Vaccine Development - BioPharm International
Rule 10b5-1 plan drives Moderna, Inc. (NASDAQ: MRNA) CEO stock sales - Stock Titan
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations - Pharmaceutical Technology
Moderna (MRNA) Wins FDA Flu Vaccine Approval On Questions Over Whether The Stock Is Fully Valued - simplywall.st
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones - Yahoo Finance
Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moderna Inc. Stock Climbs 9.9%, Outperforms Peers - Bitget
For Moderna’s Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off - Yahoo Finance
What Moderna is and how it built its mRNA vaccine platform - qz.com
FDA Approves New, More Effective Flu Vaccine From Moderna - People.com
Expert available: FDA approves 1st mRNA flu shot, from Moderna | Newswise - newswise.com
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain - MedCity News
Opinion | The FDA, Replimune and a New Flu Shot - wsj.com
FDA approves Moderna’s mFlu vaccine for adults 50 and older - CBS News
Here’s what the first mRNA flu vaccine could mean for flu season - Science News
The flu shot finally gets an upgrade - vox.com
Moderna Stock Flashing Intriguing ‘Buy The Dip’ Signal - Forbes
Moderna shares slide despite mFlusiva success 📉 What's next for the mRNA vaccines market giant? - XTB.com
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine - Yahoo Finance
FDA approved Moderna's mRNA flu vaccine after initially refusing to review it - qz.com
Moderna wins FDA approval for first mRNA-based flu shot - americanbazaaronline.com
Moderna Just Got FDA Clearance for Flu Vaccine. The Stock Is Sliding. - Barron's
FDA approves Moderna mRNA flu shot - CNBC
FDA Approves mFLUSIVA, First mRNA-Based Flu Vaccine - Drug Topics
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine - Benzinga
Moderna’s First mRNA Flu Shot Just Won FDA Approval. Now Researchers See Potential for HIV and Malaria - inc.com
Moderna's flu shot wins FDA approval after initial regulatory battle - The Business Journals
US FDA approves first mRNA flu shot from Moderna - Reuters
FMR reports 51.8M Moderna (MRNA) shares in a 13.1% ownership stake - Stock Titan
Piper Sandler reiterates Moderna stock rating on flu vaccine approval - Investing.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):